Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Comparative efficacy and safety of second-line treatments for advanced non-small cell lung cancer with wild-type or unknown status for epidermal growth factor receptor: a systematic review and network meta-analysis

Fig. 1

Flow diagram of the selection of trials for second-line treatments in advanced NSCLC with wild-type or unknown status for EGFR. ° Details in Appendix 6; * Additional articles not identified by searching bibliographic databases; $ 5 trials (10 reports) with chemotherapy (i.e., docetaxel or pemetrexed) at the investigators’ discretion. The last search for randomized trials was conducted on June 6, 2017

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us